Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2007-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JAC/DKM328PMID 17855727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.

  2006cited by this paper
• In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts

  2006cited by this paper
• Effect of Granulocyte Colony-Stimulating Factor Combination Therapy on Efficacy of Posaconazole (SCH56592) in an Inhalation Model of Murine Pulmonary Aspergillosis

  2004cited by this paper
• In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs.

  2003cited by this paper
• Invasive fungal infections in hematology: new trends

  2002cited by this paper
• Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole

  2002cited by this paper
• Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

  2002cited by this paper
• Aspergillosis case-fatality rate: systematic review of the literature.

  2001cited by this paper
• In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida

  2000cited by this paper
• Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys

  2000cited by this paper
• Efficacy of SCH56592 in a Rabbit Model of Invasive Aspergillosis

  2000cited by this paper
• Aspergillus fumigatus and Aspergillosis

  1999cited by this paper
• Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts

  1998cited by this paper
• SCH56592 treatment of murine invasive aspergillosis.

  1998cited by this paper
• Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

  1997cited by this paper
• Treatment of invasive aspergillosis.

  1994cited by this paper
• Model of recurrent pulmonary aspergillosis in rats

  1991cited by this paper
• Inactivity of terbinafine in a rat model of pulmonary aspergillosis

  1990cited by this paper
• Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis

  1988cited by this paper
• MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp

  1988cited by this paper
• Nephrotoxicity of antifungal agents.

  1985cited by this paper

• Global status and trends of invasive pulmonary aspergillosis: A bibliometric study

  2025cites this paper
• Drug repurposing reveals posaconazole as a CYP11A1 inhibitor enhancing anti-tumor immunity

  2025cites this paper
• Oral delivery of posaconazole-loaded phospholipid-based nanoformulation: Preparation and optimization using design of experiments, machine learning, and TOPSIS methods.

  2024cites this paper
• Disposition of posaconazole after single oral administration in large falcons (Falco spp): Effect of meal and dosage and a non-compartmental model to predict effective dosage.

  2021cites this paper
• Pharmacokinetics of posaconazole in koalas (Phascolarctos cinereus) after intravenous and oral administration

  2017cites this paper
• Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization

  2017cites this paper
• In vivo molecular microimaging of pulmonary aspergillosis.

  2013cites this paper
• Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis.

  2013cites this paper
• The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.

  2012cites this paper
• Antifungal Activity of Leaves of Mangroves Plant Acanthus licifolius Against Aspergillus fumigatus

  2012cites this paper
• In vivo and in situ imaging of experimental invasive pulmonary aspergillosis using fibered confocal fluorescence microscopy.

  2012cites this paper
• 2-pentylfuran: biosynthesis by Aspergillus fumigatus in-vitro and investigation of confounders of a breath test in-vivo

  2012cites this paper
• Antifungal Activity of Leaves of Mangroves Plant Acanthus licifolius Against Aspergillus fumigatus

  2012cites this paper
• Concentration of Antifungal Agents within Host Cell Membranes: a New Paradigm Governing the Efficacy of Prophylaxis

  2011cites this paper
• Innovative Antimykotika zur Therapie invasiver Pilzinfektionen

  2011cites this paper
• [Innovative antifungals for treatment of invasive fungal infections].

  2011cites this paper
• Prophylaxis of Invasive Fungal Infections: A Review of the Use of Posaconazole

  2009cites this paper
• Use of posaconazole in the treatment of invasive fungal infections

  2009cites this paper
• Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update

  2009cites this paper
• Invasive aspergillosis: diagnosis, prophylaxis and treatment

  2008cites this paper
• Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.

  2008cites this paper